Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2840 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-07-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Renal Cell Carcinoma, Renal Cell (Advanced)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Advanced Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Nexavar (Sorafenib, BAY43-9006)

Intervention Type DRUG

Patients with a diagnosis of advanced RCC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nexavar (Sorafenib, BAY43-9006)

Patients with a diagnosis of advanced RCC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Sorafenib

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bayer HealthCare AG

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Argentina

Site Status

Many Locations, , Austria

Site Status

Many Locations, , China

Site Status

Many Locations, , Colombia

Site Status

Many Locations, , Czechia

Site Status

Many Locations, , France

Site Status

Many Locations, , Germany

Site Status

Many Locations, , Greece

Site Status

Many Locations, , Indonesia

Site Status

Many Locations, , Mexico

Site Status

Many Locations, , Netherlands

Site Status

Many Locations, , Philippines

Site Status

Many Locations, , Poland

Site Status

Many Locations, , Russia

Site Status

Many Locations, , Slovakia

Site Status

Many Locations, , Slovenia

Site Status

Many Locations, , South Korea

Site Status

Many Locations, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Ireland Morocco Portugal Singapore South Africa Thailand Argentina Austria China Colombia Czechia France Germany Greece Indonesia Mexico Netherlands Philippines Poland Russia Slovakia Slovenia South Korea Sweden